Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit
Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. Learn how you can help make a difference by joining the All of Us Research Program.
Displaying 61 - 70 of 261
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendr
Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)
Protocol No
NEURO-ROCHE-METEOROID
GORE ENFORM Biomaterial Product Study: A Study to Describe Multi-use Biomaterial Performance in Hernia Patients Undergoing Open Hernia Repair Procedures
Biomaterial Product Study
Protocol No
SURG-GORE-ENFORM
Categories
A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy
Daily Subcutaneous Metreleptin Treatment in Patients With FPLD
Protocol No
ENDO-AMRYT-APG-20
Categories
A Randomized, Open-Label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in Comparison with Atezolizumab Plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A randomized study to compare Atezolizumab plus Chemotherapy vs HLX10 plus Chemo in ES-SCLC
Protocol No
SHB-HLX10-005-SCLC301-E
Categories
A Phase II Trial of De-escalated PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
A Phase 2 Trial of PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Allogenic HCT
Protocol No
IIT-ABEDIN-PTCY-RUX-GVHD
Categories
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Collection of research data and samples from patients who experience immunotherapy side effects
Protocol No
ALLIANCE-A151804
LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer
Protocol No
SWOG-LUNGMAP
Categories
Phase II Study of PD-1 Inhibition with Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy
This project is being done to assess the effectiveness of adding the drug Cemiplimab to the standard neoadjuvant chemotherapy regimen in patients with estrogen receptor and/or progesterone receptor positive, HER2 negative, or triple-negative invasive breast cancer.
Protocol No
IIT-CHAUDHARY-PD1-CEMIPLIMAB
Categories
A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab Versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors
To test if HBI-8000 is a safe and effective addition to the treatment for Melanoma
Protocol No
HBI-8000-303
Categories
Randomized Controlled Trial for Postpartum Antihypertensive Treatment of Women with Preeclampsia (P-PAT Study)
Preeclamptic Postpartum Antihypertensive Treatment (P-PAT)
Protocol No
OBG-IIT-PALATNIK-P-PAT
Categories